Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Debt to Equity (2016 - 2025)

Fortress Biotech has reported Debt to Equity over the past 13 years, most recently at $1.05 for Q4 2025.

  • Quarterly results put Debt to Equity at $1.05 for Q4 2025, up 102.98% from a year ago — trailing twelve months through Dec 2025 was $1.05 (up 102.98% YoY), and the annual figure for FY2025 was $1.05, up 102.98%.
  • Debt to Equity for Q4 2025 was $1.05 at Fortress Biotech, up from $0.73 in the prior quarter.
  • Over the last five years, Debt to Equity for FBIO hit a ceiling of $38.35 in Q4 2023 and a floor of -$35.26 in Q4 2024.
  • Median Debt to Equity over the past 5 years was $0.33 (2021), compared with a mean of -$0.68.
  • Peak annual rise in Debt to Equity hit 1991.23% in 2023, while the deepest fall reached 590.57% in 2023.
  • Fortress Biotech's Debt to Equity stood at $0.19 in 2021, then skyrocketed by 864.64% to $1.83 in 2022, then surged by 1991.23% to $38.35 in 2023, then plummeted by 191.94% to -$35.26 in 2024, then surged by 102.98% to $1.05 in 2025.
  • The last three reported values for Debt to Equity were $1.05 (Q4 2025), $0.73 (Q3 2025), and $1.34 (Q2 2025) per Business Quant data.